Replay available

Gossamer Bio, Inc. (GOSS) Q1 2026 Earnings Call

Gossamer Bio, Inc. (NASDAQ: GOSS) Q1 2026 earnings conference call, held 2026-05-18. Replay captured from the company's public earnings webcast.

Mon, May 18, 2026 at 8:00 AMendedReplay
Gossamer Bio, Inc. (GOSS) Q1 2026 Earnings Call

Hosted by

Featured presenters

Brian Gerardo

Chief Operating Officer and Chief Financial Officer

Fahim Hasning

Chief Executive Officer

Karen Peterson

Head of Regulatory Affairs

Dr. Rob Resigno

CT-FRI Substudy Lead

Bob Smith

Chief Commercial Officer

Dr. Jean-Marie Bruy

FRI Platform Expert

Vamil Devant

Analyst, Guggenheim Securities

Unknown Participant

Analyst

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Gossamer Bio, Inc..

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.031 -- 00:00:04.418 Thank you for standing by. My name is Tina, and I will be your conference operator today. 00:00:04.418 -- 00:00:09.466 At this time, I would like to welcome everyone to the Gossamer Dio 00:00:09.466 -- 00:00:11.188 Q1 2026 00:00:11.188 -- 00:00:16.837 earnings call. All lines have been placed on mute to prevent any background noise. 00:00:16.837 -- 00:00:20.443 After the speaker's remarks, there will be a question and answer session. 00:00:20.443 -- 00:00:25.431 To ask a question, simply press star 1 on your telephone keypad. 00:00:25.431 -- 00:00:28.499 To withdraw your question, press star 1 again. 00:00:28.499 -- 00:00:33.667 It is now my pleasure to turn the call over to Brian Gerardo, Chief Operating Officer 00:00:33.667 -- 00:00:38.011 and Chief Financial Officer. Please go ahead. 00:00:38.755 -- 00:00:40.557 Good morning, and thank you for joining us. 00:00:40.557 -- 00:00:44.484 Before we begin, I'd like to remind listeners that today's discussion includes forward-looking 00:00:44.484 -- 00:00:49.311 statements, including statements regarding our regulatory plans, potential NDA submission, 00:00:49.311 -- 00:00:53.858 and approval timing, commercialization, expectations, cash runway, capital structure, 00:00:53.858 -- 00:00:57.676 and the potential therapeutic benefit in future developments of Sarah Lutonit. 00:00:57.676 -- 00:01:01.641 These statements are subject to risks and uncertainties that could cause actual results 00:01:01.641 -- 00:01:06.627 to differ materially. Please refer to our SEC filings in today's press release for discussions 00:01:06.627 -- 00:01:11.133 of these risks. We undertake no obligation to update these forward-looking statements 00:01:11.133 -- 00:01:14.194 except as required by law. 00:01:14.33...